Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help

1,621 results

  1. NLM Digital Collections - Chimeric antigen receptor T-cell therapy for B-cell cancers : effectiveness and value : final ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, March 23, 2018
    resource.nlm.nih.gov/101744954
    ... Due Grade Neuro- Grade 3/4 Treatment- Prolonged B-Cell Reference Medication CRS AEs To AE 3/4 CRS ...
  2. Ethics Review - Axicabtagene Ciloleucel (Yescarta) - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK595342
    ... axicabtagene ciloleucel CAR chimeric antigen receptor LBCL large B-cell lymphoma References 1. EUnetHTA Joint Action 2 Work Package 8. ... Ciloleucel (Yescarta): CADTH Reimbursement Review: Therapeutic area: Large B-cell lymphoma [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; ... of Included Publications Other titles in this ...
  3. Checklists for Screening References - Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Health Technology Assessment ... 
    https://www.ncbi.nlm.nih.gov/books/NBK550133
    ... Checklists for Screening References - Axicabtagene Ciloleucel for Large B-Cell L... Checklists for Screening References - Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Health ...
  4. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65738
    ... B-cell lymphoma: 2.6%. Primary mediastinal large B-cell lymphoma: 0%. References Murphy SB, Fairclough DL, Hutchison RE, et al.: ... in treating patients with newly diagnosed primary mediastinal B-cell lymphoma. Patients ... References Leoncini L, Raphael M, Stein H, et al.: ...
  5. Mechanistic and Other Relevant Data - Ingested Nitrate and Nitrite, and Cyanobacterial Peptide Toxins - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK326539
    ... that higher doses are probably toxic, particularly to B lymphocytes. 4.5 References Azevedo SMFO, Carmichael WWW, Jochimsen EM, et al. ...
  6. Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK613359
    ... virus vaccination in patients with lymphoma who receive B-cell–directed therapies.[ 29 , 30 ] References Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin ...
  7. Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK592890
    ... virus vaccination in patients with lymphoma who receive B-cell–directed therapies.[ 29 , 30 ] References Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin ...
  8. Non-Hodgkin Lymphoma Treatment During Pregnancy (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK592891
    ... B-Cell Non-Hodgkin Lymphoma section in Indolent B-Cell Non-Hodgkin Lymphoma Treatment. References Nicklas AH, Baker ME: Imaging strategies in the ... newborn was otherwise healthy and recovered the circulating B lymphocytes by age 6 months with ... References Ward FT, Weiss RB: Lymphoma and pregnancy. Semin ...
  9. Pharmacoeconomic Review - Blinatumomab (Blincyto) - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK619742
    ... Canada's Drug Agency. Blincyto for MRD-positive B-cell precursor ALL — Details . 2020 [sponsor submitted reference]. 31. pan-Canadian Pharmaceutical Alliance. Acute Lymphoblastic Leukemia ( ...
  10. Rectal Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65965
    ... atypical Burkitt lymphoma. For more information, see Indolent B-Cell Non-Hodgkin Lymphoma Treatment . References Kang H, O'Connell JB, Leonardi MJ, et ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last